Loading
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Previous close
$31.12
−$0.56 · -1.77%
After-hours
$30.68
−$0.44 · -1.41%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Day range
Current $31.12
52-week range
Current $31.12
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
58
Mixed
Risk
27
Moderate Risk
Momentum
84
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Day range
Current $31.12
52-week range
Current $31.12
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 124.48M EUR | 98.56M EUR | 65.58M EUR | 57.38M EUR | 35.79M EUR |
| Selling, general, and administrative | 45.34M EUR | 47.12M EUR | 31.34M EUR | 29.34M EUR | 18.35M EUR |
| Operating expenses | 169.82M EUR | 145.69M EUR | 96.91M EUR | 86.71M EUR | 54.14M EUR |
| Interest income | — | 5.47M EUR | — | 16.11 EUR | 267.51 EUR |
| Interest expense | — | — | — | 16.11K EUR | 278.18K EUR |
| Depreciation and amortization | 418.35K EUR | 269.56K EUR | 257.55K EUR | 152.94K EUR | 77.37K EUR |
| Operating income | −169.82M EUR | −145.69M EUR | −96.91M EUR | −86.71M EUR | −54.14M EUR |
| Net income | −175.7M EUR | −134.22M EUR | −100.88M EUR | −76.33M EUR | −42.73M EUR |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$60.73
95.15% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB7.92M0.08%10.41B USD0.44%$200.48-1.41%
iShares Core MSCI EAFE ETFIEFA4.12M0.00%189.19B USD0.07%$95.87-0.34%
iShares MSCI EAFE Small-Cap ETFSCZ2.64M0.02%12.79B USD0.40%$83.25-0.44%
iShares MSCI Netherlands ETFEWN1.67M0.24%703.27M USD0.50%$66.18-0.82%
Fidelity Nasdaq Composite Index ETFONEQ826.28K0.01%10.94B USD0.21%$107.13-1.22%
iShares U.S. Small-Cap Equity Factor ETFSMLF475.83K0.01%4.11B USD0.15%$84.80+0.20%
iShares International Country Rotation Active ETFCORO411.64K0.00%13.03B USD1.06%$35.95-0.83%
Virtus Biotech Clinical Trials ETFBBC327.25K0.80%41.11M USD0.65%$43.10-0.43%iShares Biotechnology ETFIBBiShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZiShares MSCI Netherlands ETFEWNFidelity Nasdaq Composite Index ETFONEQiShares U.S. Small-Cap Equity Factor ETFSMLFiShares International Country Rotation Active ETFCOROVirtus Biotech Clinical Trials ETFBBCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
